ArticleRadiation oncology (London, England)2025
Efficacy and safety of stereotactic body radiotherapy for hepatocellular carcinoma with tumor thrombus in right atrium: a two-center retrospective review.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundWe sought to evaluate the efficacy and toxicity of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma with tumor thrombus in right atrium (RATT).
methodsHCC patients with RATT treated with SBRT at two institutions between June 2017 to July 2023 were analyzed. SBRT was generated to target the RATT. The primary endpoint was local control (LC) rate and incidence of SBRT-related pulmonary embolism (PE). The second endpoint were progression-free survival (PFS) and overall survival (OS) rate. Kaplan-Meier method was used to estimate PFS and OS. Univariate and multivariate analysis were used to identify predictors of survival.
resultsTwenty-two HCC patients with RATT underwent SBRT were analyzed. The median follow-up was 7.8 months. At one-month post-SBRT, 2 (9.5%) achieved complete response (CR), 13 (61.9%) achieved partial response (PR), and 6 (28.6%) patients were stable disease (SD). At three months post-SBRT, imaging assessments were available for 12 patients, demonstrating an improved response rate, with 4 patients (33.3%) achieving CR, 6 patients (50.0%) demonstrating PR, and 2 patients (16.7%) exhibiting SD. Pulmonary embolism (PE) was observed in two cases. One patient developed PE after receiving two fractions of SBRT, while the other experienced PE eight months post-SBRT. Median PFS was 3.3 months, while median OS was 7.8 months. The 3-month, 6-month, 9-month and 12-month overall survival rate was 77.3%, 54.5%, 45.5% and 31.8%, respectively. The 3-month, 6-month, 9-month and 12-month progression-free survival rate was 50.0%, 31.8%, 27.3% and 18.2%, respectively. Multivariate analysis identified that Child-Pugh score, prior TACE and immunotherapy history before SBRT were predictors of survival.
conclusionsIn the largest case series of SBRT for RATT to date, SBRT achieved high local control with low rates of severe toxicity, suggesting SBRT is a safe and efficient treatment option for HCC patients with RATT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.